What records are connected here?
- Evidence lanes
- 3
- Source years
- 17
- Drugs@FDA applications
- 4
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Large human trialsHormones · Cancer
Triptorelin is a lab-made decapeptide (ten amino acids) that mimics gonadotropin-releasing hormone (GnRH), and is the active ingredient in Trelstar.1,2 FDA approved Trelstar in 2000 for advanced prostate cancer. With continued use it shuts down the pituitary signal that drives testosterone production.1,2 In the randomized trials described in its label, more than 90% of men reached castration levels of testosterone within about a month and stayed there through the study.1
| What it is | A synthetic decapeptide agonist analogue of GnRH, the hypothalamic hormone that controls the pituitary’s reproductive hormones, according to the label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Trelstar with an original approval date of June 15, 2000, for advanced prostate cancer. The cited label has no boxed warning.1,2 |
| Human evidence | Two randomized, active-controlled trials and one single-arm trial in men with advanced prostate cancer, described in the label, measuring testosterone suppression.1 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Triptorelin is a synthetic analogue of gonadotropin-releasing hormone (GnRH), a ten-amino-acid peptide made in the hypothalamus.1
In the United States it is the active ingredient of Trelstar, approved under NDA 020715, according to Drugs@FDA.2
The label states that triptorelin was about 100 times more active than natural GnRH at releasing luteinizing hormone in laboratory studies of rat pituitary cells.1
Continued exposure desensitizes the pituitary, so testosterone falls to levels seen after surgical castration. The label notes that testosterone can briefly rise in the first weeks, which may temporarily worsen prostate cancer.1
In a randomized trial of 277 men with advanced prostate cancer, the label reports that 91.2% of evaluable men given Trelstar reached castration levels of testosterone by day 29, and 96.2% stayed at those levels from day 57 to day 253.1
In a randomized trial of 346 men comparing two Trelstar versions, 97.7% of evaluable men on the longer-acting version reached castration levels by day 29, according to the label.1
These trials measured testosterone, a hormone marker. The label’s clinical studies section does not report survival results for Trelstar.1
Evidence-strength label: Large randomized human trials. How this label is assigned
Yes. Drugs@FDA lists Trelstar, application NDA 020715, with an original approval date of June 15, 2000.2
The Trelstar label cited here (DailyMed SPL version 20, published July 10, 2026) states that it is indicated for the treatment of advanced prostate cancer.1
The label has no boxed warning. Its warnings cover allergic reactions, the early testosterone flare, metabolic changes such as high blood sugar, and an increased risk of heart attack, sudden cardiac death and stroke reported in men.1
How testosterone suppression with triptorelin translates into survival compared with other treatments: the label’s trials measured hormone levels.1
Long-term effects of sustained low testosterone, which the label lists among its warnings, including effects on metabolism and the heart.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Triptorelin: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Triptorelin are a bounded selection, not every registration or paper about Triptorelin. For the years before Triptorelin was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Triptorelin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Triptorelin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Trelstar for advanced prostate cancer. Randomized trials described in the label found that most men reached and kept castration levels of testosterone. The trials measured hormone suppression rather than survival.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Trelstar for advanced prostate cancer. Randomized trials described in the label found that most men reached and kept castration levels of testosterone. The trials measured hormone suppression rather than survival.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 9, 2026
Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial.↗Added to PeptideScanner November 15, 2026Literature metadata · added November 15, 2026
Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial.↗Source date November 9, 2026Literature metadata · added November 15, 2026
A phase II trial with new triptorelin sustained release formulations in prostatic carcinoma.↗Source date October 19, 2026Clinical trials · added November 15, 2026
ClinicalTrials.gov record NCT07816562↗Source date September 11, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
27 of 30 selected trial records include at least one phase value; 30 of 30 include a status value in the retained structured contract.
A phase value is unavailable here for 3 selected records; this is not counted as “no phase.”
30 of 30 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00003026 at 2026-11-15T21:49:16.513Z. Its registry update date was 2012-07-02, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00066690 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-08-26, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00066703 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-02-06, and PeptideScanner's reviewed identity mapping was triptorelin.
30 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span June 15, 2000 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 25990480 in Archives of gynecology and obstetrics as Clinical Trial, Comparative Study, Journal Article, with publication-date metadata of 2015-05-20 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 12092661 in International urology and nephrology as Clinical Trial, Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2001 (year precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07816562 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was triptorelin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06513962 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was triptorelin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00066690 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-08-26, and PeptideScanner's reviewed identity mapping was triptorelin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05982093 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-04-24, and PeptideScanner's reviewed identity mapping was triptorelin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05896566 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-02-24, and PeptideScanner's reviewed identity mapping was triptorelin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00066703 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-02-06, and PeptideScanner's reviewed identity mapping was triptorelin.↗
Literature metadata
PubMed lists PMID 10525370 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, with publication-date metadata of 1999-11 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 19888782 in Clinical drug investigation as Clinical Trial, Phase III, Journal Article, Multicenter Study, with publication-date metadata of 2009 (year precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 29177573 in Drugs as Journal Article, Review, with publication-date metadata of 2017-12 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07128394 at 2026-11-15T21:49:16.513Z. Its registry update date was 2025-08-19, and PeptideScanner's reviewed identity mapping was triptorelin.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026